

# Patrick T F Kennedy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2012652/publications.pdf>

Version: 2024-02-01

43  
papers

2,998  
citations

361413

20  
h-index

302126

39  
g-index

46  
all docs

46  
docs citations

46  
times ranked

3726  
citing authors

#	ARTICLE	IF	CITATIONS
1	The human liver microenvironment shapes the homing and function of CD4 <sup>+</sup> T-cell populations. <i>Gut</i> , 2022, 71, 1399-1411.	12.1	19
2	Differential immunogenicity of homologous versus heterologous boost in Ad26.COVS vaccine recipients. <i>Med</i> , 2022, 3, 104-118.e4.	4.4	38
3	Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 978-993.	3.7	9
4	Early Treatment Consideration in Patients with Hepatitis B Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift?. <i>Viruses</i> , 2022, 14, 900.	3.3	6
5	Chronic hepatitis B: the demise of the "inactive carrier" phase. <i>Hepatology International</i> , 2021, 15, 290-300.	4.2	22
6	Clinical and occupational health management of healthcare workers living with chronic hepatitis B: UK policy and international comparisons. <i>Journal of Viral Hepatitis</i> , 2021, 28, 976-981.	2.0	5
7	HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. <i>Biomedicines</i> , 2021, 9, 1352.	3.2	1
8	Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2021, 70, 2337-2348.	12.1	36
9	PWE-38...The Impact of Metabolic Risk Factors on Treated Chronic Hepatitis B Patients. , 2021, , .		0
10	The Î²-NGF/TrkA Signalling Pathway Is Associated With the Production of Anti-Nucleoprotein IgG in Convalescent COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 813300.	4.8	5
11	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	7.3	52
12	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	3.7	208
13	Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis. <i>Gut</i> , 2020, 69, 1907-1912.	12.1	14
14	Early treatment of chronic hepatitis B in children: Everything to play for?. <i>Journal of Hepatology</i> , 2020, 72, 802-803.	3.7	1
15	Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel disease. <i>Gut</i> , 2020, 69, 2053-2054.	12.1	0
16	Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection. <i>Gastroenterology</i> , 2020, 159, 652-664.	1.3	102
17	The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics. <i>Journal of Viral Hepatitis</i> , 2019, 26, 4-15.	2.0	12
18	Dynamics and genomic landscape of CD8 <sup>+</sup> T cells undergoing hepatic priming. <i>Nature</i> , 2019, 574, 200-205.	27.8	135

#	ARTICLE	IF	CITATIONS
19	HBV antiviral immunity: not all CD8 T cells are born equal. <i>Gut</i> , 2019, 68, 770-773.	12.1	21
20	PTU-089...Hepatitis B screening prior to rituximab and subsequent management to reduce the risk of reactivation. , 2019, , .		1
21	Emerging tools in the changing landscape of chronic hepatitis B management. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 943-955.	4.4	4
22	Fine needle aspirates comprehensively sample intrahepatic immunity. <i>Gut</i> , 2019, 68, 1493-1503.	12.1	65
23	Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. <i>Gut</i> , 2018, 67, gutjnl-2017-314873.	12.1	40
24	HBV infection and HCC: the "dangerous liaisons"™. <i>Gut</i> , 2018, 67, 787-788.	12.1	20
25	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. <i>Molecular Therapy</i> , 2018, 26, 2553-2566.	8.2	20
26	A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in Hepatitis B e antigen-negative chronic hepatitis B. <i>Annals of Gastroenterology</i> , 2018, 31, 712-721.	0.6	4
27	Reply. <i>Gastroenterology</i> , 2017, 152, 1246-1247.	1.3	0
28	IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. <i>Journal of Experimental Medicine</i> , 2017, 214, 1567-1580.	8.5	259
29	Current therapeutic approaches for HBV infected patients. <i>Journal of Hepatology</i> , 2017, 67, 412-414.	3.7	11
30	Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity. <i>Journal of Hepatology</i> , 2017, 67, 687-699.	3.7	47
31	TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. <i>Scientific Reports</i> , 2017, 7, 5514.	3.3	14
32	Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. <i>Viruses</i> , 2017, 9, 96.	3.3	57
33	CXCR6 marks a novel subset of T-betloEomeshi natural killer cells residing in human liver. <i>Scientific Reports</i> , 2016, 6, 26157.	3.3	220
34	HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. <i>Gastroenterology</i> , 2016, 151, 986-998.e4.	1.3	312
35	Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. <i>PLoS Pathogens</i> , 2016, 12, e1005788.	4.7	54
36	Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk?. <i>Journal of Infectious Diseases</i> , 2015, 211, 374-382.	4.0	75

#	ARTICLE	IF	CITATIONS
37	Hepatitis delta virus testing, epidemiology and management: A multicentre cross-sectional study of patients in London. <i>Journal of Clinical Virology</i> , 2015, 66, 33-37.	3.1	39
38	New insights in the management of chronic hepatitis B. <i>Clinical Medicine</i> , 2015, 15, 191-196.	1.9	10
39	Chronic hepatitis B virus in young adults: the need for new approaches to management. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1045-1053.	4.4	6
40	Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. <i>Journal of Experimental Medicine</i> , 2013, 210, 99-114.	8.5	286
41	Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 143, 637-645.	1.3	257
42	Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. <i>Hepatology</i> , 2011, 53, 1494-1503.	7.3	283
43	Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. <i>PLoS Pathogens</i> , 2010, 6, e1001227.	4.7	228